Get started

Volumespreadanalysis

$BKSY Next Target PTs 4-4.75 Long term PT 29 and higherBlackSky Technologies Inc. (NYSE: BKSY) was awarded a basic order agreement from the Joint Artificial Intelligence Center (JAIC) to create and optimize data sets for use in DoD AI models and applications. The JAIC agreement has a ceiling value of $241 million over five years. BlackSky Technology Inc. provides geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operations of satellite and ground systems to commercial and government customers worldwide. The company processes a range of observations from its constellation, as well as various space, internet-of-things, and terrestrial based sensors and data feeds. Its products are used in government defense and intelligence; commercial, construction, and industrial; and catastrophe, climate, and environment applications. The company was incorporated in 2014 and is headquartered in Herndon, Virginia.
NYSE:BKSYLong
by BADQOMOCAWGOWLD
Showcase: Trading the e-mini Dow Jones (YM) 22-06-201. Did a long trade (paper trading) on e-mini Dow Jones. 2. Reason for the long trade: a) Price do a higher lower; a UT bar appears but the next bar overtake the UT. b) Volume is supporting the upward move. c) Strong support level at 29910 range. 3. Trade entered with SL @ 50pts and TP @ 75pts; as price move upwards with unrealised profit, the SL is revised upwards to minimise the losses and eventually lock-in the profit. 4. Price eventually do a pullback after breaking the recent Resistance (29966 range); our SL got hit and we exited with a realised profit of 24pts. 5. Price may move upwards from hereon; it is OK to exit with a small profit rather than be ambitious.
CBOT_MINI:YM1!Long
by mdalifalwi
$MREO Next Target PTs 2.50-4.50 and higher^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
NASDAQ:MREOLong
by BADQOMOCAWGOWLD
$AERC entry PTs 16-17.70 Next Target PT 28 and higher Long term AeroClean Technologies, Inc., an interior space air purification technology company, provides air purification solutions for hospitals and other healthcare facilities. The company offers interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. It provides Purgo, an air sanitization product for indoor spaces; and Purgo Lift that provides air purification solution for elevators and other wall-mount applications. The company was formerly known as AeroClean Technologies, LLC. AeroClean Technologies, Inc. was founded in 2011 and is headquartered in Palm Beach Gardens, Florida.
ALong
by BADQOMOCAWGOWLD
$AUVI Next Target PT 4.50 and higher Long term PT 35 and higherApplied UV, Inc., through its subsidiaries, develops, acquires, and commercializes technology that addresses air purification and infection control in the healthcare, hospitality, commercial, municipal, and residential markets in the United States, Canada, and Europe. It operates through Disinfection and Hospitality segments. The company offers science-based solutions and products in air purification under the Airocide brand; and disinfection of hard surfaces under the Lumicide brand. It also manufactures and supplies fine decorative framed mirrors, framed arts, and bathroom vanities. The company was incorporated in 2019 and is headquartered in Mount Vernon, New York.
ALong
by BADQOMOCAWGOWLD
1
$SIDU Long term PT 59 and higher Timeline: Jan 2023Sidus Space is a Teammate on NASA’s $3.5 Billion Exploration Extravehicular Activity Services Contract Sidus Space, Inc., a space-as-a-service company, engages in the design, manufacture, launch, and data collection of commercial satellite worldwide. Its services include satellite manufacturing; precision manufacturing, assembly, and test; low earth orbit microsatellite; payload integrations; launch and support services; space-based data services and analytics; precision computer numerical control machining and fabrication; Swiss screw machining; wire cable harness fabrication; 3D composite and metal printing; and satellite deployment and microgravity testing and research services, as well as services related to electrical and electronic assemblies. The company also offers hardware solutions consisting of an external flight test platform to develop, test, and fly experiments, as well as delivers hardware, materials, and advanced electronics on the international space station; and space station integrated kinetic launcher for orbital payload systems. It serves commercial space, aerospace, defense, underwater marine, and other commercial and government customers. The company was founded in 2014 and is headquartered in Merritt Island, Florida. Sidus Space, Inc. is a subsidiary of Craig Technical Consulting, Inc.
NASDAQ:SIDULong
by BADQOMOCAWGOWLD
1
$BTTX entry PTs 1.30-1.40 Long term PT 17-50 and higherBetter Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
BLong
by BADQOMOCAWGOWLD
$QNGY entry PTs .40-.45 Long term PT 40 and higher Quanergy Systems, Inc. develops and markets light detection and ranging (LiDAR) solutions for automotive and IoT applications. The company offers M1 LiDAR sensor for mid-long range industrial measurement applications; M1 Edge 2D LiDAR sensor that enables reliable collision avoidance and smart navigation; M8 LiDAR sensor, which provides 3D perception using multiple eye-safe laser beams and time-of-flight measurement technology; MQ-8 LiDAR sensor for flow management applications; M8-Prime 3D LiDAR sensor that provides industry-leading pinpoint accuracy and captures for industrial and mapping applications; S3 solid state LiDAR sensor; QORTEX DTC, a 3D computer perception software; and QORTEX people counter enables the development of accurate and innovative people counting and queue management applications. Its products are used in various applications, such as mapping, security, smart city and smart spaces, industrial automation, and transportation applications. The company was founded in 2012 and is headquartered in Sunnyvale, California.
QLong
by BADQOMOCAWGOWLD
LaVinci's 30-Day PlanUnfortunately, we cannot predict the future. We can, however, predict the immediate future as a function of our free will in conflict with the universe around us. In anticipation of BTCUSD dropping to the 22,000 area, as a bearish harmonic extension distributes' itself, LaVinci has devised a plan to accumulate BTCUSD over the course of the next month. The goal is to avert risk while simultaneously reap rewards by scaling into multiple LONG positions over the course of the above mentioned time period (30 days). Stop-Losses are also devised in the plan to scale out and liquidate the long positions in the event that the current structure fails to react accordingly. Take-Profits aren't being taken into account just yet, for the anticipated time that this position will be held is going to be between 70-90 days. Please follow & critique, as critical feedback is strongly encouraged! Thanks, LaVinci
BITSTAMP:BTCUSDLong
by LaVinci
1
One of Most Bullish Days for Ethereum: $750 billion Shorts As per liquidation information on the digital currency market given by IP TRADE, Ethereum saw one of the greatest liquidation volumes over the most recent couple of months, on the off chance that not years, with nearly $800 Billion worth of orders being vanished from the market. Such a huge liquidation volume showed up after Ethereum skipped off the helpline at $1,715 and acquired around 4% of its worth. The crush has undoubtedly seemed due to dealers' and financial backers' conviction that the second greatest digital money available will dip under $1,700 and hurry to the following help at around $1,500.
BITSTAMP:ETHUSDLong
by IPatrice
4
GBPUSD - Buy Compression 🚨This should be very obvious compression to you. Price may give an initial lure but long term sells aren't ready until we get a strong liquidity grab into the supply zones above. I will be searching for buys to join banks for when they decide to complete compression. The daily and weekly POC are very close to each other, this zone had the most volume because it was full of sellers trying to use the area as resistance. If price pulls back and uses this area as a fresh demand, I will be going long. I will keep you updated all day.
Long
by AlkalineFX
18